ImmunityBio, Inc.
- Open
- 7.55
- Day high
- 7.58
- Day low
- 7.43
- Prev close
- 7.65
- Volume
- 4.8M
- Mkt cap
- $8.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- -7.7
- P/S
- 48.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$3.9M over the last 3 months (0 open-market buys, 6 sales)
- 🏛Institutions accumulating (13F)
ImmunityBio, Inc. (IBRX) is a Healthcare company listed on NASDAQ. The stock is up 193% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 6 sales (SEC Form 4).
ImmunityBio, Inc. (IBRX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
IBRX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 4, 2026 | $-0.08 | $-0.22 | -175.0% | $51M | +3.1% |
| May 7, 2026 | $-0.08 | $-0.09 | -12.5% | $44M | +2.6% |
| Mar 3, 2025 | $-0.26 | $-0.15 | +42.3% | $8M | -21.5% |
| May 9, 2024 | $-0.16 | $-0.20 | -25.0% | $40000 | +100.0% |
| Mar 19, 2024 | $-0.18 | $-0.19 | -5.6% | $139000 | +595.0% |
| May 11, 2023 | $-0.27 | $-0.27 | +0.0% | $360000 | +0.0% |
| Mar 1, 2023 | $-0.22 | $-0.27 | -22.7% | $73000 | +192.0% |
| Nov 9, 2022 | $-0.23 | $-0.28 | -21.7% | $118000 | +0.0% |
| Mar 1, 2022 | $-0.21 | $-0.23 | -9.5% | $390000 | +1460.0% |
| Nov 12, 2021 | $-0.20 | $-0.22 | -10.0% | $66000 | +230.0% |
| Aug 12, 2021 | $-0.12 | $-0.23 | -91.7% | $339000 | +43.7% |
| May 14, 2021 | $-0.41 | $-0.21 | +48.8% | $139000 | -25.3% |
IBRX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 6, 2026 | Selecky Christobeldirector | Option | 35,064 | $2.98 |
| Jul 6, 2026 | Selecky Christobeldirector | Option | 124,414 | $2.99 |
| Jul 6, 2026 | Selecky Christobeldirector | Sell | 159,478 | $9.02 |
| Jul 6, 2026 | Cohen Cheryldirector | Sell | 131,210 | $9.50 |
| Jul 6, 2026 | Cohen Cheryldirector | Option | 55,979 | $2.98 |
| Jul 1, 2026 | Selecky Christobeldirector | Sell | 1,000 | $9.00 |
| Jul 1, 2026 | Selecky Christobeldirector | Option | 300 | $2.99 |
| Jul 1, 2026 | Selecky Christobeldirector | Option | 700 | $2.98 |
| Jul 1, 2026 | Selecky Christobeldirector | Sell | 95,722 | $9.01 |
| Jul 1, 2026 | Selecky Christobeldirector | Option | 30,000 | $2.84 |
| Jul 1, 2026 | Selecky Christobeldirector | Option | 33,549 | $2.99 |
| Jul 1, 2026 | Selecky Christobeldirector | Option | 32,173 | $2.98 |
| Jun 26, 2026 | Simon Barry J.director | Sell | 25,000 | $7.88 |
| Jun 10, 2026 | Selecky Christobeldirector | Grant | 65,600 | $7.25 |
| Jun 10, 2026 | Cohen Cheryldirector | Grant | 65,600 | $7.25 |
Source: IBRX SEC Form 4 filings, latest Jul 6, 2026. For informational purposes only — not investment advice.
See the full IBRX insider & 13F page →ImmunityBio, Inc. company profile
Overview
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. The company went public in 2015 and focuses on developing innovative therapies and vaccines to treat cancers and infectious diseases. ImmunityBio operates at the cutting edge of immunotherapy and cell therapy, leveraging the body's immune system to fight diseases that have traditionally been difficult to treat.
Business
ImmunityBio operates in the biotechnology sector, specifically focusing on immunotherapy and cell therapy platforms for treating cancer and infectious diseases. The biotechnology industry involves using biological processes and living organisms to develop medical treatments, representing one of the most innovative areas of modern medicine. The company's core offerings span multiple therapeutic platforms. Their antibody cytokine fusion proteins combine antibodies that target specific disease markers with cytokines that stimulate immune responses, essentially creating guided missiles that can both find cancer cells and activate the immune system to destroy them. They also develop synthetic immunomodulators, which are artificially created compounds that can enhance or modify immune system function. ImmunityBio's vaccine technologies focus on training the immune system to recognize and attack specific pathogens or cancer cells. Their natural killer (NK) cell therapies involve using specialized immune cells that can directly kill cancer cells without prior exposure. Additionally, their adaptive T cell immune systems work by enhancing T cells, which are crucial components of the immune system that can remember and respond to specific threats. The company's therapeutic pipeline includes treatments in Phase II or III clinical trials targeting various cancers including bladder, pancreatic, and lung cancers. They also develop treatments for infectious diseases, particularly focusing on pathogens like SARS-CoV-2 and HIV. This diversified approach allows them to address both oncology and infectious disease markets, which represent some of the largest unmet medical needs globally.
Revenue model
ImmunityBio's business model is typical of clinical-stage biotechnology companies, primarily focused on research and development with minimal current revenue generation. The company's revenue streams are currently limited, generating approximately $14.7 million in 2024, primarily from collaboration agreements and licensing deals with various partners including the National Cancer Institute, National Institute of Deafness and Communication Disorders, and commercial partners like Amyris, Inc. The company operates through strategic partnerships and licensing agreements with organizations such as CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, and others. These partnerships provide upfront payments, milestone payments, and potential future royalties, though the amounts are currently modest relative to operating expenses. As a clinical-stage company, ImmunityBio's ultimate revenue model depends on successfully advancing their therapeutic candidates through clinical trials and obtaining regulatory approval. Once approved, they would generate revenue through product sales either directly or through partnerships with larger pharmaceutical companies. The company may also monetize their platform technologies through additional licensing deals. Several factors could significantly impact the company's margins and financial performance. Regulatory approval success rates are critical, as biotechnology companies face high failure rates in clinical trials. Competition from larger pharmaceutical companies with greater resources could pressure pricing and market share. Healthcare reimbursement policies and pricing pressures from government and insurance providers could limit revenue potential. Conversely, successful clinical trial results, breakthrough therapy designations from regulators, and strategic partnerships with major pharmaceutical companies could dramatically improve the company's financial prospects and market position.
Competitive moat
ImmunityBio's competitive moat is relatively narrow and primarily based on intellectual property and scientific expertise rather than traditional business advantages. The company's moat stems from their proprietary platform technologies, particularly their antibody cytokine fusion proteins and natural killer cell therapies, which are protected by patents and represent years of specialized research and development. The biotechnology industry is characterized by high barriers to entry due to regulatory requirements, substantial capital needs, and scientific complexity. However, these barriers also apply to ImmunityBio's competitors, many of whom have significantly greater financial resources. The company's scientific team and accumulated knowledge in immunotherapy represent valuable assets, but this expertise can potentially be replicated by competitors with sufficient investment. The company faces substantial competitive threats from large pharmaceutical companies with established immunotherapy programs, such as Bristol Myers Squibb, Merck, and Roche, which have greater financial resources, larger research teams, and established commercial infrastructure. Additionally, numerous other biotechnology companies are pursuing similar immunotherapy approaches, creating a crowded competitive landscape. ImmunityBio's moat is further weakened by their limited financial resources relative to competitors and their dependence on external funding to continue operations. The company's ability to maintain competitive advantages depends heavily on successful clinical trial outcomes and their ability to secure additional capital. Without breakthrough clinical results or strategic partnerships, the company's competitive position could deteriorate rapidly as cash resources are depleted.
Risks & safety
ImmunityBio presents significant financial risks with a very narrow margin of safety for investors. • Cash burn and solvency risk: The company burned $398 million in free cash flow during 2024 with only $143 million in cash and short-term investments as of Q4 2024, suggesting approximately 4-5 quarters of runway at current burn rates • Debt levels: Total liabilities of $871 million significantly exceed total assets of $383 million, creating a negative book value of approximately $488 million • Valuation metrics: Negative earnings make traditional valuation metrics challenging; trading at negative P/E ratios due to substantial losses • Revenue generation: Minimal revenue of $14.7 million in 2024 against operating losses exceeding $400 million annually • Dilution risk: High probability of additional equity raises needed for continued operations, which would dilute existing shareholders • Clinical trial risks: Company's value depends entirely on successful clinical trial outcomes, with high historical failure rates in biotechnology
Recent development
Based on the available financial data, ImmunityBio has been focused on advancing their clinical pipeline while managing significant cash burn. The company has maintained a diversified approach to immunotherapy development, with multiple therapeutic candidates in various stages of clinical trials targeting both cancer and infectious diseases. The company has been actively pursuing strategic partnerships and collaborations to supplement their research capabilities and potentially reduce development costs. Their partnerships with government agencies like the National Cancer Institute and National Institute of Deafness and Communication Disorders provide validation for their scientific approach while offering potential funding support. Revenue generation has remained minimal but showed some improvement, increasing from $622,000 in 2023 to $14.7 million in 2024, primarily through collaboration agreements and licensing deals. However, this revenue growth has been insufficient to offset the substantial operating expenses associated with clinical trial activities and research and development. The company has been managing their cash position carefully, though burn rates remain high at approximately $400 million annually. They have maintained a reasonable current ratio above 3.0, indicating sufficient short-term liquidity, but the overall financial trajectory suggests the need for additional capital raises to continue operations beyond 2025.
IBRX company profile · for informational purposes only — not investment advice.
Track IBRX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free